BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 12719509)

  • 1. Cost evaluation of risperidone compared with olanzapine.
    Byerly MJ; Weber M; Brooks D; Casey SB; Elliot S; Hawkins J
    Psychiatr Serv; 2003 May; 54(5):742-4. PubMed ID: 12719509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risperidone compared with olanzapine in a naturalistic clinical study: a cost analysis.
    Taylor DM; Wright T; Libretto SE;
    J Clin Psychiatry; 2003 May; 64(5):589-97. PubMed ID: 12755664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of discharge rates and drug costs for patients with schizophrenia treated with risperidone or olanzapine.
    Kelly DL; Nelson MW; Love RC; Yu Y; Conley RR
    Psychiatr Serv; 2001 May; 52(5):676-8. PubMed ID: 11331805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A retrospective economic evaluation of olanzapine versus risperidone in the treatment of schizophrenia.
    Zhao Z
    Manag Care Interface; 2002 Feb; 15(2):75-81. PubMed ID: 11875967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic evaluations of olanzapine and risperidone.
    Shaw JW
    Am J Health Syst Pharm; 2002 Jul; 59(14):1366-75. PubMed ID: 12132564
    [No Abstract]   [Full Text] [Related]  

  • 6. Olanzapine and risperidone.
    Love RC; Kelly DL
    Am J Health Syst Pharm; 2003 Mar; 60(5):487-8; author reply 488-9. PubMed ID: 12635459
    [No Abstract]   [Full Text] [Related]  

  • 7. Olanzapine versus risperidone in the treatment of schizophrenia : a comparison of costs among Texas Medicaid recipients.
    Rascati KL; Johnsrud MT; Crismon ML; Lage MJ; Barber BL
    Pharmacoeconomics; 2003; 21(10):683-97. PubMed ID: 12828491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [RODOS: risperidone olanzapine drug outcome studies in schizophrenia].
    De Beauchamp I; Giraud-Baro E; Gury C
    Encephale; 2002; 28 Spec No 2 Pt 2():S33-4. PubMed ID: 12587356
    [No Abstract]   [Full Text] [Related]  

  • 9. Association of co-morbidities with prescribing patterns and cost savings: olanzapine versus risperidone for schizophrenia.
    Yu W; Ren XS; Lee AF; Herz L; Huang YH; Kazis LE
    Pharmacoeconomics; 2006; 24(12):1233-48. PubMed ID: 17129077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Olanzapine: an updated review of its use in the management of schizophrenia.
    Bhana N; Foster RH; Olney R; Plosker GL
    Drugs; 2001; 61(1):111-61. PubMed ID: 11217867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Service use and costs among VA patients with schizophrenia taking risperidone or olanzapine.
    Fuller MA; Shermock KM; Secic M; Laich JS; Durkin MB
    Psychiatr Serv; 2002 Jul; 53(7):855-60. PubMed ID: 12096169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Olanzapine versus risperidone. A prospective comparison of clinical and economic outcomes in schizophrenia.
    Edgell ET; Andersen SW; Johnstone BM; Dulisse B; Revicki D; Breier A
    Pharmacoeconomics; 2000 Dec; 18(6):567-79. PubMed ID: 11227395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug utilization patterns and outcomes associated with in-hospital treatment with risperidone or olanzapine.
    Procyshyn RM; Zerjav S
    Clin Ther; 1998; 20(6):1203-17; discussion 1192-3. PubMed ID: 9916613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost analysis of the treatment of schizophrenia in the UK. A simulation model comparing olanzapine, risperidone and haloperidol.
    Almond S; O'Donnell O
    Pharmacoeconomics; 2000 Apr; 17(4):383-9. PubMed ID: 10947493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of atypical antipsychotics in a Veterans Affairs hospital.
    Schwartz TL; Saba M; Hardoby W; Virk S; Masand PS
    Prog Neuropsychopharmacol Biol Psychiatry; 2002 Oct; 26(6):1207-10. PubMed ID: 12452548
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A cost-effectiveness clinical decision analysis model for schizophrenia.
    Palmer CS; Revicki DA; Genduso LA; Hamilton SH; Brown RE
    Am J Manag Care; 1998 Mar; 4(3):345-55. PubMed ID: 10178497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Olanzapine vs risperidone in the management of schizophrenia: a randomized double-blind trial in Australia and New Zealand.
    Gureje O; Miles W; Keks N; Grainger D; Lambert T; McGrath J; Tran P; Catts S; Fraser A; Hustig H; Andersen S; Crawford AM
    Schizophr Res; 2003 Jun; 61(2-3):303-14. PubMed ID: 12729882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacy cost evaluation of risperidone, olanzapine, and quetiapine for the treatment of schizophrenia in acute care inpatient settings.
    Mladsi DM; Grogg AL; Irish WD; Lopez RB; Degen K; Swann A; Nimsch CT
    Curr Med Res Opin; 2004 Dec; 20(12):1883-93. PubMed ID: 15701206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Olanzapine. A pharmacoeconomic review of its use in schizophrenia.
    Foster RH; Goa KL
    Pharmacoeconomics; 1999 Jun; 15(6):611-40. PubMed ID: 10538333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Service use and costs of treating schizophrenia with atypical antipsychotics.
    Lewis M; McCrone P; Frangou S
    J Clin Psychiatry; 2001 Oct; 62(10):749-56. PubMed ID: 11816863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.